Y. Zhong

Trastuzumab Plus Endocrine Therapy or Chemotherapy as First-line Treatment for Patients with Hormone Receptor–Positive and HER2-Positive Metastatic Breast Cancer (SYSUCC-002)

Ying Lin, X. An, Zhongyu Yuan, 2021, Clinical cancer research : an official journal of the American Association for Cancer Research.

Effect of Capecitabine Maintenance Therapy Using Lower Dosage and Higher Frequency vs Observation on Disease-Free Survival Among Patients With Early-Stage Triple-Negative Breast Cancer Who Had Received Standard Treatment: The SYSUCC-001 Randomized Clinical Trial.

X. An, L. Cai, Ying Lin, 2020, JAMA.

Trastuzumab plus endocrine therapy or chemotherapy as first-line treatment for metastatic breast cancer with hormone receptor-positive and HER2-positive: The sysucc-002 randomized clinical trial.

Ying Lin, X. An, Zhongyu Yuan, 2021 .

Trastuzumab Plus Endocrine Therapy or Chemotherapy as First-line Treatment for Patients with Hormone Receptor–Positive and HER2-Positive Metastatic Breast Cancer (SYSUCC-002)

Ying Lin, X. An, Zhongyu Yuan, 2021, Clinical Cancer Research.

High-dose tamoxifen in high-hormone-receptor-expressing advanced breast cancer patients: a phase II pilot study

Zhongyu Yuan, Yanxia Shi, X. Bi, 2021, Therapeutic advances in medical oncology.

The Effects of Ganglioside-Monosialic Acid in Taxane-induced Peripheral Neurotoxicity in Patients with Breast Cancer: A Randomized Trial.

J. Unger, X. An, L. Cai, 2019, Journal of the National Cancer Institute.

Trastuzumab Plus Endocrine Therapy or Chemotherapy as First-line Treatment 1 for Patients with Metastatic Breast Cancer with Hormone Receptor-positive and 2 HER2-positive (SYSUCC-002)

Ying Lin, X. An, Zhongyu Yuan, 2021 .

Sam68 expression and cytoplasmic localization is correlated with lymph node metastasis as well as prognosis in patients with early-stage cervical cancer.

S. Jiang, Y. Zhong, H. Tu, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.